Replimune stock surged 101% after Cantor Fitzgerald upgraded it to 'Overweight', citing the exit of FDA biologics chief Vinay Prasad as removing a key obstacle to RP1’s approval. Analysts believe the chances of accelerated clearance for the skin cancer drug have improved, while retail sentiment turned 'extremely bullish' with message volume soaring over 1,000%.